微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 61.65% | -2.41% | 8.8% | 44/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 56.66% | -6.5% | -7.73% | 62/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 61.41% | -1.74% | -0.36% | 48/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 61.63% | -2.89% | -2.44% | 49/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 63.17% | -2.84% | 4.24% | 43/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 60.6% | 4.11% | -3.02% | 52/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 62.49% | 8.57% | -1.53% | 47/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 63.46% | 10.32% | -2.39% | 50/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 65.02% | 2.12% | 11.69% | 41/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 58.21% | 16.14% | 1.13% | 63/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 57.56% | 12.84% | 0.06% | 64/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 57.53% | 14.01% | -9.64% | 67/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 63.67% | 55.12% | 27.02% | 48/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 50.12% | -8.58% | -1.75% | 86/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 51.01% | 27.34% | 1.1% | 72/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 50.46% | -9.68% | -7.97% | 79/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 54.82% | 28.93% | -1.86% | 72/159 | -144.37% | 艾力斯 | 99.4% | 行业排名> |
| 2020-06-30 | 55.86% | 32.43% | 31.38% | 62/159 | 54.32% | 首药控股 | 99.94% | 行业排名> |
| 2019-12-31 | 42.52% | -5.01% | 6.14% | 94/159 | -1213.38% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-09-30 | 40.06% | 2% | -5.04% | 79/159 | 55.47% | 微芯生物 | 95.14% | 行业排名> |
| 2019-06-30 | 42.19% | 2% | 2.78% | 78/159 | 55.47% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-03-31 | 41.04% | 2% | -8.31% | 74/159 | 51.37% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | 44.76% | 2% | 2% | 81/159 | -205.91% | 微芯生物 | 96.09% | 行业排名> |